AI Article Synopsis
- The study aimed to evaluate how the lockdown from March 17 to May 11, 2020, affected patients with exudative age-related macular degeneration who received anti-VEGF injections at a university hospital.
- Researchers analyzed data from 595 eyes of 493 patients, comparing initial and final visual acuity, finding a slight decline of 1.13 letters, which was not significant.
- The conclusion indicated that while visual acuity was generally maintained during the lockdown, missing scheduled injections was the primary reason for significant visual decline in patients.
Article Abstract
Purpose: To assess the impact of the measures taken during the lockdown period from March 17 to May 11, 2020 on the management of patients with exudative age related macular degeneration treated by intravitreal anti-VEGF injections at the University Hospital of Tours.
Methods: In this retrospective study, patients were included after analysis of the computerized medical records of patients with age related macular degeneration. Those who were treated for exudative age related macular degeneration who received at least 1 intravitreal injection in the 12 months prior and at least one consultation in the 6 months prior to the lockdown period, were included. The initial and final mean visual acuity were compared with a 5 letter non-inferiority margin. A subgroup analysis was performed according to outcomes. The visual acuities immediately after this period were also recorded.
Results: In all, 595 eyes of 493 patients were included. The mean initial visual acuity was 59.6 letters, vs. 58.5 for the final visual acuity, i.e. a difference of -1.13 letters with a lower limit of the confidence interval of less than 5. The visual acuity on release from lockdown was comparable to the other 2 measurements. Initial visual acuity and the number of missed treatments were the main factors associated with functional loss.
Conclusion: Patients' visual acuity during the lockdown period was able to be maintained despite the restrictive measures and limitation of care access in France. The most common cause of substantial visual decline was missed intravitreal injections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jfo.2022.11.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NR2E3-Associated Retinopathy Presenting with Bilateral Choroidal Neovascularization.
Retin Cases Brief Rep
October 2024
Singapore National Eye Centre, Singapore.
Purpose: We describe an atypical presentation of an 11-year-old female with enhanced S-cone syndrome (ESCS).
Methods: Case report. The patient underwent a thorough ophthalmic examination and investigations such as colour fundus photography, optical coherence tomography, fundus autofluorescence, fluorescein and indocyanine angiography, an electroretinogram and genetic testing.
Topographic changes in macula and its association with visual outcomes in idiopathic epiretinal membrane surgery.
PLoS One
January 2025
Department of Ophthalmology, Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Purpose: We investigated changes in macular topography and their association with visual acuity and metamorphopsia in the idiopathic epiretinal membrane (iERM).
Methods: Twenty-four eyes that underwent vitrectomy and ERM removal with internal limiting membrane peeling were included in this study. Best-corrected visual acuity (BCVA) and horizontal/vertical metamorphopsia scores (h and vM-scores in the M-chart) were assessed.
Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium.
PLoS One
January 2025
Verana Health, San Francisco, CA, United States of America.
Purpose: To evaluate prevalence and incidence rates of pigmentary maculopathy and retinopathy (PM/PR), and visual acuity (VA) changes in patients exposed to pentosan polysulfate sodium (PPS) and in patients with interstitial cystitis (IC) not exposed to PPS.
Methods: This is a retrospective cohort study (January 2015-March 2021) which included adult de-identified patients from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and Komodo Health database. Three patient cohorts were identified: two PPS-exposed patient cohorts, and Non-PPS-exposed IC patient cohort.
Safety and Vision Outcomes Following Gene Therapy for Bietti Crystalline Dystrophy: A Nonrandomized Clinical Trial.
JAMA Ophthalmol
January 2025
Xiamen Eye Center of Xiamen University, Xiamen, Fujian, China.
Importance: Bietti crystalline dystrophy (BCD) is a severe genetic retinopathy caused by variants in the CYP4V2 gene. Currently, there is no approved treatment for BCD.
Objective: To evaluate safety and vision outcomes following gene therapy with adeno-associated virus (AAV) encoding CYP4V2 (rAAV-hCYP4V2, NGGT001 [Next Generation Gene Therapeutics]).
Attractive and repulsive visual aftereffects depend on stimulus contrast.
J Vis
January 2025
Laboratoire des Systèmes Perceptifs, Département d'études cognitives, École normale supérieure, PSL University, France.
Visual perception has been described as a dynamic process where incoming visual information is combined with what has been seen before to form the current percept. Such a process can result in multiple visual aftereffects that can be attractive toward or repulsive away from past visual stimulation. A lot of research has been conducted on what functional role the mechanisms that produce these aftereffects may play.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!